CMG Pharmaceutical Co. Ltd   Report issue

For profit Phase 1
Founded: Seoul Korea, Republic of (2001)

Organization Overview

First Clinical Trial
2015
NCT02501109
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

CMG Pharmaceutical Co. Ltd

Active Ingredients

Drugs in Phase 1 Trials (2)

aripiprazole (abilify) (1 trial)

nov1601 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Schizophrenia (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 2